News

ADA: Nighttime system reduces hypoglycemia events in children with type 1 diabetes


 

AT THE ADA ANNUAL SCIENTIFIC SESSIONS

References

BOSTON – A system to detect dropping blood glucose and suspend insulin delivery during sleep is safe and effective in children with type 1 diabetes as young as 4 years, according to results of a randomized controlled trial.

In a presentation to the annual scientific sessions of the American Diabetes Association, Dr. Bruce A. Buckingham of Stanford (Calif.) University showed that the system, which combines glucose monitoring with insulin pump connected wirelessly to a computer by the patient’s bedside, worked nearly as well in children as it had in a previous study enrolling adults (Diabetes Care 2014;37:1885-91).

Dr. Buckingham and his colleagues enrolled 36 children aged 4-10 years and 45 children aged 11-14 years. All the children had type 1 diabetes for a year or more and had been using an insulin pump at least 6 months. The youngsters had hemoglobin A1c levels of 8% or lower, and the investigators confirmed the presence of nighttime hypoglycemia during 2 weeks of pretrial monitoring. The children were then randomized to the active or inactive system for 42 nights, of which 21 were active. Patients were not aware whether the system was active on any given night.

Insulin delivery was suspended when the computer predicted glucose would fall below 80 mg/dL within 30 minutes, to anticipate and prevent further drops to levels of 60 mg/dL or lower that could, if prolonged, trigger a seizure.

Unlike other systems for continuous glucose monitoring that alert patients of dropping glucose, this one used alarms only when levels dropped below 60 mg/dL. More often than not, Dr. Buckingham said, “people do not awaken to alarms.” The idea “is for the system to work in the background – a good night’s sleep without a seizure.”

Dr. Buckingham and his colleagues found that among about 1,900 nights recorded in the 11- to 14-year-old subgroup, the active system reduced the number of nights children’s glucose fell below 60 mg/dL for 2 hours or more from 8% in the control group to 3% in the active system (P < .001). Among about 1,600 nights monitored in the 4- to 10-year-olds, prolonged hypoglycemia was reduced from 5% of nights in the control group to 1% in the active group (P < .001).

Although younger children have a higher risk of fasting ketonemia that can be increased with insulin pump shut-offs, no episodes of ketosis occurred during the study, and there were no seizures.

The National Institute of Diabetes and Digestive and Kidney Diseases funded the study. Dr. Buckingham disclosed advisory or consulting relationships with Medtronic, Sanofi, Novo Nordisk, Tandem, and ConvaTec.

Recommended Reading

Maternal obesity, not mild GDM, affects childhood BMI
MDedge Pediatrics
Recent data suggest little pancreatic risk with incretin medications
MDedge Pediatrics
Medicare is stingy in first year of doctor bonuses
MDedge Pediatrics
Gastric emptying more rapid in adolescents with type 1 diabetes
MDedge Pediatrics
High-dose oral insulin offers immunotherapy hope against type 1 diabetes
MDedge Pediatrics
PAS: Genetic testing for MODY deemed increasingly cost effective
MDedge Pediatrics
PAS: Getting a grip on glucokinase MODY
MDedge Pediatrics
PAS: New approaches for cystic fibrosis–related diabetes in development
MDedge Pediatrics
PAS: Mind-body practices benefit teens with chronic illnesses
MDedge Pediatrics
PAS: Start sulfonylureas before genetic testing in neonatal diabetes
MDedge Pediatrics